论文部分内容阅读
分别用含VP-16的CEP和EP方案及含VM-26的VM-26+DDP和VM-26+Carboplatin方案合并放射治疗小细胞肺癌患者共74例,以比较二者的近、远期疗效和毒副作用。结果示:VP-16组有效率为90.7%,VM-26组为93.55%;VP-16组的两年存活率为44.19%,VM-26组为48.39%;VP-16组的脑转移率为14%,VM-26组为12.9%;VP-16组的3~4级血液毒性发生率为27.91%,VM-26组为58.06%。提示VP-16与铂类联合的CEP,EP方案和VM-26+DDP,VM-26+Carboplatin方案均可视为治疗小细胞肺癌的有效方案。VM-26对预防小细胞肺癌的脑转移未见显著优势
A total of 74 patients with small cell lung cancer were treated with CEP and EP regimens containing VP-16 and VM-26+DDP and VM-26+Carboplatin regimens with VM-26, respectively, to compare the near, long-term efficacy, and side effects of both. The results showed that the effective rate was 90.7% in the VP-16 group and 93.55% in the VM-26 group; the two-year survival rate was 44.19% in the VP-16 group and 48.39% in the VM-26 group; The brain metastasis rate was 14% in the VP-16 group and 12.9% in the VM-26 group; the hematologic toxicity rate in the 3-4 group was 3.9 in the VP-16 group and 58.06% in the VM-26 group. . The combination of VP-16 and platinum-based CEP, EP regimen, VM-26+DDP, and VM-26+Carboplatin regimen can be regarded as an effective treatment for small cell lung cancer. VM-26 has no significant advantage in preventing brain metastasis of small cell lung cancer